Bayer Boosts Gene Therapy Presence With AskBio Buy
Deal Could Be Worth $4bn
After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.
